H_2受体拮抗剂用于抑制由化疗引起的恶心呕吐的临床研究  

Clinical trial of efficacy of H_2 receptor antagonist on restraint of emesis induced by chemotherapy

作　　者：郑伟华[1] 饶珈琦[2] 谢德荣[3] 詹锋[4] 张华[1] 

机构地区：[1]广东省人民医院肿瘤内科,广东广州510080 [2]广东省人民医院消化内科,广东广州510080 [3]中山大学附属第二医院肿瘤科,广东广州510120 [4]广东省人民医院中医科,广东广州510080

出　　处：《肿瘤防治杂志》2004年第11期1203-1205,共3页China Journal of Cancer Prevention and Treatment

摘　　要：基于含铂或中度以上致呕肿瘤化疗方案 ,应用 5 HT3 受体拮抗剂为基础的止呕方法 ,对 12 6例病理学确诊为晚期恶性肿瘤患者按 2∶1信封法随机分组进行跟踪治疗 ,研究组加用H2 受体拮抗剂和安定 ,而对照组加用地塞米松 ,并从疗效、不良反应、耐受性及安全性等方面对两分组加以分析比较。研究组对抑制急性恶心呕吐有效率为91 2 % ( 73 / 80 ) ,迟缓性恶心呕吐有效率为 87 5 % ( 70 / 80 ) ,而对照组分别为 71 7% ( 3 3 / 46)及 60 9% ( 2 8/ 46) ,两分组相比差异有统计学意义 ,P值分别为 0 0 0 4及 0 0 0 1;加救援治疗后 ,研究组总完全控制率 10 0 % ( 80 / 80 ) ,对照组仅70 % ( 2 8/ 46) ,两组间差异也有统计学意义 ,P =0 0 0 0。初步研究结果提示 ,以 5 HT3 受体拮抗剂为基础加H2 受体拮抗剂和安定的止呕方法对由含铂或中度以上致呕肿瘤化疗方案所引起的恶心呕吐有明显的抑制作用 ,尤其是在迟缓性呕吐方面 ,有效率高 ,不良反应小 ,患者有良好的耐受性及安全性。Found on platinum-based or with above-moderate level of emesis-induction chemotherapy scenarios, used the 5-HT 3 receptor antagonist as an essential emesis restraint to treat 126 patients with advanced malignant tumor, by using the Randomized Controlled Trial (RCT) method at 2∶1, added H 2 receptor antagonist and Valium to the 5-HT 3 receptor antagonist in the experiment group, and added Dexamethason to the 5-HT 3 receptor antagonist in the reference group. The results were observed and compared between the two groups in terms of efficacy, adverse effects, tolerance, and safety. The effective rate of the experiment group on the restraint of emesis was 91.2%(73/80) for acute vomiting; and 87.5%(70/80) for delayed emesis, while the effective rate of the reference group was 71.7%(33/46)and 60.9%(28/46), respectively, and the corresponding P value was 0.004 and 0.001, respectively. The efficacy differences between the two groups were significant statistically. After using the antiemetic rescue, the rate of full control of nausea /emesis was 100%(80/80) for the experiment group, whereas the reference group was 70%(28/46),P value was 0.000. These differences were also significant statistically. Adding H 2 receptor antagonist and Valium to the essential 5-HT 3 receptor antagonist as an anti-emesis on platinum-based, or with above-moderate level of emesis-induction chemotherapy scenarios has a significantly high effective rate (especially on restraining delayed emesis), little adverse effects and provides the patient with good tolerance and safety.

关 键 词：肿瘤/药物疗法 受体 组氨H2 恶心 呕吐 安定/治疗应用 

分 类 号：R730.5[医药卫生—肿瘤]